[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,148,636
  • Shares Outstanding, K 84,026
  • Annual Sales, $ 0 K
  • Annual Income, $ -313,940 K
  • EBIT $ -320 M
  • EBITDA $ -319 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.39

Options Overview Details

View History
  • Implied Volatility 102.17% (-12.52%)
  • Historical Volatility 264.51%
  • IV Percentile 4%
  • IV Rank 3.56%
  • IV High 667.58% on 10/15/25
  • IV Low 81.32% on 12/17/25
  • Expected Move (DTE 3) 1.23 (9.02%)
  • Put/Call Vol Ratio 1.49
  • Today's Volume 15,231
  • Volume Avg (30-Day) 25,945
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 215,818
  • Open Int (30-Day) 252,119
  • Expected Range 12.44 to 14.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.71
  • Number of Estimates 4
  • High Estimate $-0.64
  • Low Estimate $-0.76
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +25.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.76 +186.90%
on 07/29/26
14.12 -3.19%
on 08/10/26
+2.68 (+24.39%)
since 07/10/26
3-Month
3.62 +277.62%
on 05/11/26
14.12 -3.19%
on 08/10/26
+9.60 (+235.87%)
since 05/08/26
52-Week
1.50 +811.33%
on 04/13/26
14.12 -3.19%
on 08/10/26
+8.38 (+158.41%)
since 08/08/25

Most Recent Stories

More News
REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Replimune Group, Inc. (“Replimune” or the “Company”)...

REPL : 13.67 (+13.35%)
REPL INVESTOR ALERT: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuit

SAN DIEGO , Aug. 10, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) securities between October...

REPL : 13.67 (+13.35%)
REPL Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Replimune Group, Inc.

SAN DIEGO , Aug. 10, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP  informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise...

REPL : 13.67 (+13.35%)
Replimune Announces Pricing of $150 Million Underwritten Offering

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,...

REPL : 13.67 (+13.35%)
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL

The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL ) violations of §§10(b) and 20(a)...

REPL : 13.67 (+13.35%)
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”)...

REPL : 13.67 (+13.35%)
Deadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed...

REPL : 13.67 (+13.35%)
Deadline Approaching: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith  

Law Offices of Howard G. Smith reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Replimune...

REPL : 13.67 (+13.35%)
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who...

REPL : 13.67 (+13.35%)
Law Offices of Howard G. Smith Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL...

REPL : 13.67 (+13.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 16.29
2nd Resistance Point 15.20
1st Resistance Point 14.44
Last Price 13.67
1st Support Level 12.59
2nd Support Level 11.50
3rd Support Level 10.74

See More

52-Week High 14.12
Last Price 13.67
Fibonacci 61.8% 9.30
Fibonacci 50% 7.81
Fibonacci 38.2% 6.32
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.